# Crucial Obstacles and Strategies for Human RSV Pediatric Vaccine Development

## TL;DR

This paper reviews the challenges and strategies for developing RSV vaccines for children, focusing on safety, immune response, and better animal models.

## Contribution

The paper provides a comprehensive review of obstacles and innovative strategies for pediatric RSV vaccine development.

## Key findings

- Current vaccines for adults and pregnant women do not address pediatric-specific challenges like ERD and maternal antibody interference.
- Animal models have limitations in replicating RSV infection and immune responses in infants.
- Multi-antigen strategies and improved adjuvants are critical for future vaccine success.

## Abstract

Human respiratory syncytial virus (RSV) remains a leading cause of severe lower respiratory tract infections in infants and immunocompromised populations, causing approximately 160,000 annual deaths globally. Despite recent approvals of prefusion F (pre-F) protein-based vaccines (Arexvy, Abrysvo) for older adults and pregnant women, pediatric vaccine development faces unique challenges including enhanced respiratory disease (ERD) risks, maternal antibody interference, and immature infant immune responses. Meanwhile, G protein glycosylation variability and NS1/NS2-mediated interferon suppression remain the outstanding difficulties in structure-based vaccine design. Additionally, current animal models demonstrate notable constraints in virus replication, host susceptibility, immune responses, clinical symptoms, and ERD phenomena. This review synthesizes current obstacles and innovative strategies, highlighting that the selection of multi-antigen strategies, appropriate adjuvants, and the development of more precise preclinical animal models are critical elements that will determine the efficacy and safety of future RSV vaccines.